The latest price target for Sana Biotechnology (NASDAQ:SANA) was reported by HC Wainwright & Co. on January 8, 2025. The analyst firm set a price target for $11.00 expecting SANA to rise to within 12 months (a possible 279.31% upside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Sana Biotechnology (NASDAQ:SANA) was provided by HC Wainwright & Co., and Sana Biotechnology maintained their buy rating.

The last upgrade for Sana Biotechnology Inc happened on January 8, 2025 when TD Cowen raised their price target to N/A. TD Cowen previously had a hold for Sana Biotechnology Inc.

The last downgrade for Sana Biotechnology Inc happened on November 5, 2024 when JMP Securities changed their price target from N/A to N/A for Sana Biotechnology Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sana Biotechnology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sana Biotechnology was filed on January 8, 2025 so you should expect the next rating to be made available sometime around January 8, 2026.

While ratings are subjective and will change, the latest Sana Biotechnology (SANA) rating was a maintained with a price target of $8.00 to $11.00. The current price Sana Biotechnology (SANA) is trading at is $2.90, which is out of the analyst’s predicted range.